414 related articles for article (PubMed ID: 24128715)
21. A genomic and clinicopathological study of non-small-cell lung cancers with discordant ROS1 gene status by fluorescence in-situ hybridisation and immunohistochemical analysis.
Zhao J; Chen X; Zheng J; Kong M; Wang B; Ding W
Histopathology; 2018 Jul; 73(1):19-28. PubMed ID: 29464758
[TBL] [Abstract][Full Text] [Related]
22. High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer.
Pailler E; Auger N; Lindsay CR; Vielh P; Islas-Morris-Hernandez A; Borget I; Ngo-Camus M; Planchard D; Soria JC; Besse B; Farace F
Ann Oncol; 2015 Jul; 26(7):1408-15. PubMed ID: 25846554
[TBL] [Abstract][Full Text] [Related]
23. Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer.
Rogers TM; Russell PA; Wright G; Wainer Z; Pang JM; Henricksen LA; Singh S; Stanislaw S; Grille J; Roberts E; Solomon B; Fox SB
J Thorac Oncol; 2015 Apr; 10(4):611-8. PubMed ID: 25789833
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients.
Song Z; Yu X; Zhang Y
Cancer Biol Ther; 2017 Nov; 18(11):883-887. PubMed ID: 27635639
[TBL] [Abstract][Full Text] [Related]
25. ROS1 expression and translocations in non-small-cell lung cancer: clinicopathological analysis of 1478 cases.
Warth A; Muley T; Dienemann H; Goeppert B; Stenzinger A; Schnabel PA; Schirmacher P; Penzel R; Weichert W
Histopathology; 2014 Aug; 65(2):187-94. PubMed ID: 24456475
[TBL] [Abstract][Full Text] [Related]
26. From genotype to phenotype: Are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements?
Plodkowski AJ; Drilon A; Halpenny DF; O'Driscoll D; Blair D; Litvak AM; Zheng J; Moskowitz CS; Ginsberg MS
Lung Cancer; 2015 Nov; 90(2):321-5. PubMed ID: 26424208
[TBL] [Abstract][Full Text] [Related]
27. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.
Zito Marino F; Rossi G; Cozzolino I; Montella M; Micheli M; Bogina G; Munari E; Brunelli M; Franco R
J Clin Pathol; 2020 Feb; 73(2):96-101. PubMed ID: 31562206
[TBL] [Abstract][Full Text] [Related]
28. Frequent aerogenous spread with decreased E-cadherin expression of ROS1-rearranged lung cancer predicts poor disease-free survival.
Jin Y; Sun PL; Park SY; Kim H; Park E; Kim G; Cho S; Kim K; Lee CT; Chung JH
Lung Cancer; 2015 Sep; 89(3):343-9. PubMed ID: 26149475
[TBL] [Abstract][Full Text] [Related]
29. A Prediction Model for ROS1-Rearranged Lung Adenocarcinomas based on Histologic Features.
Zhou J; Zhao J; Zheng J; Kong M; Sun K; Wang B; Chen X; Ding W; Zhou J
PLoS One; 2016; 11(9):e0161861. PubMed ID: 27648828
[TBL] [Abstract][Full Text] [Related]
30. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.
Mazières J; Zalcman G; Crinò L; Biondani P; Barlesi F; Filleron T; Dingemans AM; Léna H; Monnet I; Rothschild SI; Cappuzzo F; Besse B; Thiberville L; Rouvière D; Dziadziuszko R; Smit EF; Wolf J; Spirig C; Pecuchet N; Leenders F; Heuckmann JM; Diebold J; Milia JD; Thomas RK; Gautschi O
J Clin Oncol; 2015 Mar; 33(9):992-9. PubMed ID: 25667280
[TBL] [Abstract][Full Text] [Related]
31. Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell Lung Cancer.
Digumarthy SR; Mendoza DP; Lin JJ; Chen T; Rooney MM; Chin E; Sequist LV; Lennerz JK; Gainor JF; Shaw AT
Clin Lung Cancer; 2020 Mar; 21(2):153-159.e3. PubMed ID: 31708389
[TBL] [Abstract][Full Text] [Related]
32. Histopathologic characteristics of advanced-stage ROS1-rearranged non-small cell lung cancers.
Park E; Choi YL; Ahn MJ; Han J
Pathol Res Pract; 2019 Jul; 215(7):152441. PubMed ID: 31085007
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients.
Michels S; Scheel AH; Scheffler M; Schultheis AM; Gautschi O; Aebersold F; Diebold J; Pall G; Rothschild S; Bubendorf L; Hartmann W; Heukamp L; Schildhaus HU; Fassunke J; Ihle MA; Künstlinger H; Heydt C; Fischer R; Nogovà L; Mattonet C; Hein R; Adams A; Gerigk U; Schulte W; Lüders H; Grohé C; Graeven U; Müller-Naendrup C; Draube A; Kambartel KO; Krüger S; Schulze-Olden S; Serke M; Engel-Riedel W; Kaminsky B; Randerath W; Merkelbach-Bruse S; Büttner R; Wolf J
J Thorac Oncol; 2016 Jan; 11(1):122-7. PubMed ID: 26762747
[TBL] [Abstract][Full Text] [Related]
34. Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition.
Facchinetti F; Rossi G; Bria E; Soria JC; Besse B; Minari R; Friboulet L; Tiseo M
Cancer Treat Rev; 2017 Apr; 55():83-95. PubMed ID: 28342334
[TBL] [Abstract][Full Text] [Related]
35. Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non-small-cell Lung Cancer: Implications of FISH-positive Patterns.
Clavé S; Rodon N; Pijuan L; Díaz O; Lorenzo M; Rocha P; Taus Á; Blanco R; Bosch-Barrera J; Reguart N; de la Torre N; Oliveras G; Espinet B; Bellosillo B; Puig X; Arriola E; Salido M
Clin Lung Cancer; 2019 Jul; 20(4):e421-e429. PubMed ID: 30898567
[TBL] [Abstract][Full Text] [Related]
36. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
[TBL] [Abstract][Full Text] [Related]
37. ROS1 immunohistochemistry among major genotypes of non-small-cell lung cancer.
Boyle TA; Masago K; Ellison KE; Yatabe Y; Hirsch FR
Clin Lung Cancer; 2015 Mar; 16(2):106-11. PubMed ID: 25467930
[TBL] [Abstract][Full Text] [Related]
38. ROS1 gene rearrangement and copy number gain in non-small cell lung cancer.
Jin Y; Sun PL; Kim H; Park E; Shim HS; Jheon S; Kim K; Lee CT; Chung JH
Virchows Arch; 2015 Jan; 466(1):45-52. PubMed ID: 25374304
[TBL] [Abstract][Full Text] [Related]
39. Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.
Song A; Kim TM; Kim DW; Kim S; Keam B; Lee SH; Heo DS
Clin Cancer Res; 2015 May; 21(10):2379-87. PubMed ID: 25688157
[TBL] [Abstract][Full Text] [Related]
40. Clinical significance of ROS1 5' deletions in non-small cell lung cancer.
Capizzi E; Dall'Olio FG; Gruppioni E; Sperandi F; Altimari A; Giunchi F; Fiorentino M; Ardizzoni A
Lung Cancer; 2019 Sep; 135():88-91. PubMed ID: 31447007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]